drugset / Trial / NCT05528354
Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the effectiveness and safety of Venetoclax and Decitabin based conditioning regimen followed with post-HSCT Decitabin maintenance therapy in TP53 mutant AML/MDS Patients.
Timeline
- Start
- 2022-06-02
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabin | Unknown | 5 mg/m2 | — |
| Subject | Venetoclax | Small molecule | 200 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |
| Background | ATG | Unknown | 1.5 mg/kg | — |
| Background | ATG | Unknown | 7.5 mg/kg | — |
| Background | CTX | Unknown | 60 mg/kg | — |
| Background | CTX | Unknown | 1.8 g | — |
| Background | Cytarabine | Small molecule | 2 g | — |
| Background | Flu | Unknown | 30 mg/m2 | — |
| Background | Me-CCNU | Unknown | 250 mg/m2 | — |
| Background | Posaconazole | Small molecule | — | — |
| Background | VEN and DEC based conditioning regimen | Unknown | 0.8 mg/kg | — |
| Background | Voriconazole | Small molecule | — | — |